Eintrag weiter verarbeiten
Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients
Gespeichert in:
| Zeitschriftentitel: | Human Psychopharmacology: Clinical and Experimental |
|---|---|
| Personen und Körperschaften: | , , , |
| In: | Human Psychopharmacology: Clinical and Experimental, 22, 2007, 8, S. 505-513 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Kissling, Werner Glue, Per Medori, Rossella Simpson, Steve Kissling, Werner Glue, Per Medori, Rossella Simpson, Steve |
|---|---|
| author |
Kissling, Werner Glue, Per Medori, Rossella Simpson, Steve |
| spellingShingle |
Kissling, Werner Glue, Per Medori, Rossella Simpson, Steve Human Psychopharmacology: Clinical and Experimental Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients Pharmacology (medical) Psychiatry and Mental health Neurology (clinical) Neurology |
| author_sort |
kissling, werner |
| spelling |
Kissling, Werner Glue, Per Medori, Rossella Simpson, Steve 0885-6222 1099-1077 Wiley Pharmacology (medical) Psychiatry and Mental health Neurology (clinical) Neurology http://dx.doi.org/10.1002/hup.877 <jats:title>Abstract</jats:title><jats:p>This subgroup analysis of the 6‐month, open‐label Switch to Risperidone Microspheres (StoRMi) trial evaluated long‐term safety and efficacy of a direct conversion to risperidone long‐acting injectable (RLAI) in 52 elderly patients (≥65 years) with psychosis stabilized on oral or depot antipsychotic. Study outcomes included adverse events, movement disorder severity, psychiatric symptoms, functional ability, quality of life and patient satisfaction. Change in the Positive and Negative Syndrome Scale at endpoint was the primary efficacy measure. The most common dosage of RLAI used at endpoint was 25 mg every 14 days (60%). The trial was completed by 81% of patients, with six patients discontinuing treatment due to an adverse event. Tolerability was good and most side effects were mild to moderate. Serious adverse events occurred in 11 patients. Two of these (suicidal attempt, <jats:italic>n</jats:italic> = 1; exacerbation of disease, <jats:italic>n</jats:italic> = 1) were considered possibly related to RLAI. Conversion to RLAI resulted in significant improvements in movement disorder severity, psychiatric symptoms, functional status and patient satisfaction. Mean PANSS total decreased by 15.8 at endpoint, with 23 patients (46.9%) experiencing a ≥20% improvement. This post‐hoc analysis supports that RLAI is well tolerated and safe in elderly patients with psychotic illnesses switched from stable antipsychotic regimens, and suggests possible efficacy, although inferences are limited. Copyright © 2007 John Wiley & Sons, Ltd.</jats:p> Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients Human Psychopharmacology: Clinical and Experimental |
| doi_str_mv |
10.1002/hup.877 |
| facet_avail |
Online |
| finc_class_facet |
Chemie und Pharmazie Medizin Psychologie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9odXAuODc3 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9odXAuODc3 |
| institution |
DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 |
| imprint |
Wiley, 2007 |
| imprint_str_mv |
Wiley, 2007 |
| issn |
0885-6222 1099-1077 |
| issn_str_mv |
0885-6222 1099-1077 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
kissling2007longtermsafetyandefficacyoflongactingrisperidoneinelderlypsychoticpatients |
| publishDateSort |
2007 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Human Psychopharmacology: Clinical and Experimental |
| source_id |
49 |
| title |
Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients |
| title_unstemmed |
Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients |
| title_full |
Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients |
| title_fullStr |
Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients |
| title_full_unstemmed |
Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients |
| title_short |
Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients |
| title_sort |
long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients |
| topic |
Pharmacology (medical) Psychiatry and Mental health Neurology (clinical) Neurology |
| url |
http://dx.doi.org/10.1002/hup.877 |
| publishDate |
2007 |
| physical |
505-513 |
| description |
<jats:title>Abstract</jats:title><jats:p>This subgroup analysis of the 6‐month, open‐label Switch to Risperidone Microspheres (StoRMi) trial evaluated long‐term safety and efficacy of a direct conversion to risperidone long‐acting injectable (RLAI) in 52 elderly patients (≥65 years) with psychosis stabilized on oral or depot antipsychotic. Study outcomes included adverse events, movement disorder severity, psychiatric symptoms, functional ability, quality of life and patient satisfaction. Change in the Positive and Negative Syndrome Scale at endpoint was the primary efficacy measure. The most common dosage of RLAI used at endpoint was 25 mg every 14 days (60%). The trial was completed by 81% of patients, with six patients discontinuing treatment due to an adverse event. Tolerability was good and most side effects were mild to moderate. Serious adverse events occurred in 11 patients. Two of these (suicidal attempt, <jats:italic>n</jats:italic> = 1; exacerbation of disease, <jats:italic>n</jats:italic> = 1) were considered possibly related to RLAI. Conversion to RLAI resulted in significant improvements in movement disorder severity, psychiatric symptoms, functional status and patient satisfaction. Mean PANSS total decreased by 15.8 at endpoint, with 23 patients (46.9%) experiencing a ≥20% improvement. This post‐hoc analysis supports that RLAI is well tolerated and safe in elderly patients with psychotic illnesses switched from stable antipsychotic regimens, and suggests possible efficacy, although inferences are limited. Copyright © 2007 John Wiley & Sons, Ltd.</jats:p> |
| container_issue |
8 |
| container_start_page |
505 |
| container_title |
Human Psychopharmacology: Clinical and Experimental |
| container_volume |
22 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792338766906523655 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:37:03.983Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Long%E2%80%90term+safety+and+efficacy+of+long%E2%80%90acting+risperidone+in+elderly+psychotic+patients&rft.date=2007-12-01&genre=article&issn=1099-1077&volume=22&issue=8&spage=505&epage=513&pages=505-513&jtitle=Human+Psychopharmacology%3A+Clinical+and+Experimental&atitle=Long%E2%80%90term+safety+and+efficacy+of+long%E2%80%90acting+risperidone+in+elderly+psychotic+patients&aulast=Simpson&aufirst=Steve&rft_id=info%3Adoi%2F10.1002%2Fhup.877&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792338766906523655 |
| author | Kissling, Werner, Glue, Per, Medori, Rossella, Simpson, Steve |
| author_facet | Kissling, Werner, Glue, Per, Medori, Rossella, Simpson, Steve, Kissling, Werner, Glue, Per, Medori, Rossella, Simpson, Steve |
| author_sort | kissling, werner |
| container_issue | 8 |
| container_start_page | 505 |
| container_title | Human Psychopharmacology: Clinical and Experimental |
| container_volume | 22 |
| description | <jats:title>Abstract</jats:title><jats:p>This subgroup analysis of the 6‐month, open‐label Switch to Risperidone Microspheres (StoRMi) trial evaluated long‐term safety and efficacy of a direct conversion to risperidone long‐acting injectable (RLAI) in 52 elderly patients (≥65 years) with psychosis stabilized on oral or depot antipsychotic. Study outcomes included adverse events, movement disorder severity, psychiatric symptoms, functional ability, quality of life and patient satisfaction. Change in the Positive and Negative Syndrome Scale at endpoint was the primary efficacy measure. The most common dosage of RLAI used at endpoint was 25 mg every 14 days (60%). The trial was completed by 81% of patients, with six patients discontinuing treatment due to an adverse event. Tolerability was good and most side effects were mild to moderate. Serious adverse events occurred in 11 patients. Two of these (suicidal attempt, <jats:italic>n</jats:italic> = 1; exacerbation of disease, <jats:italic>n</jats:italic> = 1) were considered possibly related to RLAI. Conversion to RLAI resulted in significant improvements in movement disorder severity, psychiatric symptoms, functional status and patient satisfaction. Mean PANSS total decreased by 15.8 at endpoint, with 23 patients (46.9%) experiencing a ≥20% improvement. This post‐hoc analysis supports that RLAI is well tolerated and safe in elderly patients with psychotic illnesses switched from stable antipsychotic regimens, and suggests possible efficacy, although inferences are limited. Copyright © 2007 John Wiley & Sons, Ltd.</jats:p> |
| doi_str_mv | 10.1002/hup.877 |
| facet_avail | Online |
| finc_class_facet | Chemie und Pharmazie, Medizin, Psychologie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9odXAuODc3 |
| imprint | Wiley, 2007 |
| imprint_str_mv | Wiley, 2007 |
| institution | DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14 |
| issn | 0885-6222, 1099-1077 |
| issn_str_mv | 0885-6222, 1099-1077 |
| language | English |
| last_indexed | 2024-03-01T15:37:03.983Z |
| match_str | kissling2007longtermsafetyandefficacyoflongactingrisperidoneinelderlypsychoticpatients |
| mega_collection | Wiley (CrossRef) |
| physical | 505-513 |
| publishDate | 2007 |
| publishDateSort | 2007 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Human Psychopharmacology: Clinical and Experimental |
| source_id | 49 |
| spelling | Kissling, Werner Glue, Per Medori, Rossella Simpson, Steve 0885-6222 1099-1077 Wiley Pharmacology (medical) Psychiatry and Mental health Neurology (clinical) Neurology http://dx.doi.org/10.1002/hup.877 <jats:title>Abstract</jats:title><jats:p>This subgroup analysis of the 6‐month, open‐label Switch to Risperidone Microspheres (StoRMi) trial evaluated long‐term safety and efficacy of a direct conversion to risperidone long‐acting injectable (RLAI) in 52 elderly patients (≥65 years) with psychosis stabilized on oral or depot antipsychotic. Study outcomes included adverse events, movement disorder severity, psychiatric symptoms, functional ability, quality of life and patient satisfaction. Change in the Positive and Negative Syndrome Scale at endpoint was the primary efficacy measure. The most common dosage of RLAI used at endpoint was 25 mg every 14 days (60%). The trial was completed by 81% of patients, with six patients discontinuing treatment due to an adverse event. Tolerability was good and most side effects were mild to moderate. Serious adverse events occurred in 11 patients. Two of these (suicidal attempt, <jats:italic>n</jats:italic> = 1; exacerbation of disease, <jats:italic>n</jats:italic> = 1) were considered possibly related to RLAI. Conversion to RLAI resulted in significant improvements in movement disorder severity, psychiatric symptoms, functional status and patient satisfaction. Mean PANSS total decreased by 15.8 at endpoint, with 23 patients (46.9%) experiencing a ≥20% improvement. This post‐hoc analysis supports that RLAI is well tolerated and safe in elderly patients with psychotic illnesses switched from stable antipsychotic regimens, and suggests possible efficacy, although inferences are limited. Copyright © 2007 John Wiley & Sons, Ltd.</jats:p> Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients Human Psychopharmacology: Clinical and Experimental |
| spellingShingle | Kissling, Werner, Glue, Per, Medori, Rossella, Simpson, Steve, Human Psychopharmacology: Clinical and Experimental, Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients, Pharmacology (medical), Psychiatry and Mental health, Neurology (clinical), Neurology |
| title | Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients |
| title_full | Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients |
| title_fullStr | Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients |
| title_full_unstemmed | Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients |
| title_short | Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients |
| title_sort | long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients |
| title_unstemmed | Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients |
| topic | Pharmacology (medical), Psychiatry and Mental health, Neurology (clinical), Neurology |
| url | http://dx.doi.org/10.1002/hup.877 |